Reviewing SAB Biotherapeutics (NASDAQ:SABS) and Exelixis (NASDAQ:EXEL)
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and Exelixis (NASDAQ:EXEL – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the st
Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
SAB Biotherapeutics (SABS) Receives a Buy From H.C. Wainwright
SAB Biotherapeutics Gets Additional $8.2M in Funding in Closeout DoD Contract
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Received An Additional $8.2M From DoD Related To Closeout Of The Discontinued COVID-19 Prototype Research And Development Contract
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Received An Additional $8.2M From DoD Related To Closeout Of The Discontinued COVID-19 Prototype Research And Development Contract
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) shares increased by 59.5% to $3.35 during Wednesday's after-market session. This security traded at a volume of 341.5K shares come close, making up 1423.5% of i
H.C. Wainwright Remains a Buy on SAB Biotherapeutics (SABS)
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing With
EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study
SAB Biotherapeutics (NASDAQ:SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D) an
SAB Biotherapeutics' CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
SIOUX FALLS, S.D., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency,
Loading...
No Stock Yet